J&J's Tremfya fails giant cell arteritis study, where Roche and AbbVie have...
Johnson & Johnson’s streak of trial wins for its blockbuster drug Tremfya has come to an end. The blockbuster drug failed in a Phase 2 test in adults with giant cell arteritis, an autoimmune...
View ArticleFDA again rejects AbbVie's continuous infusion therapy for Parkinson's
The FDA has rejected a new Parkinson’s drug from AbbVie for a second time. Regulators turned away ABBV-951, a 24-hour infusion therapy to treat advanced Parkinson’s disease, AbbVie said Tuesday...
View ArticleCityblock Health investors buy employee shares in tender offer
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Private investors in the health services startup Cityblock Health have bought shares from employees as...
View ArticleClik here to view.
Biopharma leaders charting a path for the industry's LGBTQ+ community
Many individuals and groups, whom we’ve highlighted in the past, have made the biotech industry more welcoming for the LGBTQ+ community over the years. So for our third annual feature on LGBTQ+ leaders...
View ArticleGinkgo to cut at least 35% of staff in multi-year restructuring plan
Ginkgo is reducing its headcount by at least 35% in a multi-year restructuring plan, the company announced in a securities filing on Monday. The company laid out a plan last month to reduce its labor...
View ArticleZealand Pharma aims to raise $900M; Boehringer discontinues three Phase 2 trials
Plus, news about Lundbeck, Otsuka, Jubilant Pharma, Frontier Medicines, AstraZeneca and BenevolentAI: Zealand Pharma targets $900M raise: The Danish biotech aims to secure the funding through a private...
View ArticleClik here to view.
Wave Life Sciences touts Huntington's disease win in Phase 1b/2a trial
Wave Life Sciences said Tuesday that its experimental Huntington’s disease therapy effectively lowered the mutant huntingtin protein (mHTT) levels associated with the disease in a Phase 1b/2a trial,...
View ArticleTeva to pay $750M to resolve Israel tax disputes
Teva has agreed to pay $750 million over the next five years to settle litigation with Israel’s tax authorities. The deal settles all pending disputes over the Israel-based company’s taxes payable...
View ArticleAmgen calls Colorado's price controls on Enbrel 'unconstitutional'
Amgen on Monday called on a Colorado federal court to overturn the state drug affordability board’s decision to cap the price of Amgen’s blockbuster biologic Enbrel. The California-based company said...
View ArticleClik here to view.
Q&A: FDA medical policy chief talks decentralized trial guidance, improving...
The FDA’s director of its Office of Medical Policy wants trial sponsors to keep participant experiences top-of-mind in their decentralized designs. Endpoints News sat down with Khair ElZarrad last week...
View ArticleClik here to view.
Can CRISPR be given twice? Small study from Intellia suggests it can
A small trial exploring what happens when patients were given a second infusion of an experimental CRISPR therapy suggests that it could be safe to readminister, opening the door to treating conditions...
View ArticleClik here to view.
Lilly becomes the latest pharma to tap OpenAI for help, this time for...
First it was Moderna, then Sanofi, and now Lilly. OpenAI’s influence on the pharmaceutical industry has made its way to Indianapolis. Diogo Rau Lilly Chief Information Officer Diogo Rau said Tuesday...
View ArticleArrowhead shelves one cardiometabolic drug candidate, focuses on another
On Tuesday, Arrowhead Pharmaceuticals said it will shift focus to its experimental cardiometabolic drug plozasiran and will deprioritize its work on zodasiran, emphasizing the need to be thoughtful...
View ArticleClik here to view.
Lyell reports patient death, early responses in solid tumor CAR-T trial
In an early-stage clinical trial with a handful of patients, Lyell Immunopharma’s experimental CAR-T therapy for solid tumor cancers showed hints of efficacy but also faced significant safety concerns,...
View ArticleZealand rides obesity wave with $1B raise to advance amylin drug and look for...
Zealand Pharma is raising $1 billion to focus on its “crown jewel” — an amylin analog for weight loss — both to advance it into a Phase 2b trial and hunt for a development and commercial partner. CEO...
View ArticleAlexis Borisy and Zach Weinberg's Curie.Bio secures $380M to support...
Curie.Bio, a Cambridge, MA-based biotech accelerator that aims to “free the founders,” has raised a $380 million fund mainly to support nascent startups that graduate from its program. The fund,...
View ArticleClik here to view.
With a $372M megaround, Formation Bio looks to in-license 10+ drugs
While the bulk of AI-focused biotechs try to discover drugs and push the boundaries of biology, Benjamine Liu would rather synthesize meeting minutes than molecules. Liu’s startup, Formation Bio, is...
View ArticleFDA publishes long-awaited guidance on clinical trial diversity
As the White House kicked off a public forum on clinical trials on Wednesday, the FDA simultaneously published a delayed draft guidance on ensuring clinical trials become diverse. The draft guidance...
View ArticleNovo Nordisk takes $816M impairment loss after Phase 3 fail in chronic kidney...
Novo Nordisk said Wednesday morning a small molecule that it recently bought for up to $1.3 billion has failed a Phase 3 trial in chronic kidney disease. The Danish drugmaker said it will take an...
View ArticleClik here to view.
Savara’s rare lung disease treatment passes Phase 3
Savara reported that its daily treatment for a rare lung disease met the primary endpoint in a key late-stage study. The company is developing molgramostim for autoimmune pulmonary alveolar proteinosis...
View Article